Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/01/20
End: 04/01/24
Due: 04/01/25
Phase: N/A
Priority: Normal
Start: 03/08/19
End: 06/30/28
Due: 06/30/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | NCT04231864 | Alain Algazi | user2@example.com | None | 2020-12-01 | 2024-04-01 | 2025-04-01 | - | - | 2025-07-14 |
| Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03708224 | Alain Algazi | user2@example.com | None | 2019-03-08 | 2028-06-30 | 2029-06-30 | - | - | 2025-07-14 |